Get complete Patent Opposition Report for Alkermes Pharma Ireland

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Explore patent oppositions filed by Alkermes Pharma Ireland against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Patent NumberTitleApplicantOpposition Date
EP3866765Injectable Long-Acting Naltrexone Microparticle CompositionsCHONG KUN DANG PHARMACEUTICALNov 6, 2024
EP3566696Risperidone Sustained Release Microsphere CompositionGENEORA PHARMA SHIJIAZHUANGJul 7, 2021
EP3104844Complexes Of Sirolimus And Its Derivatives, Process For The Preparation Thereof And Pharmaceutical Compositions Containing ThemDRUGGABILITY HOLDCONov 11, 2020
EP3199146Risperidone Sustained Release Microsphere CompositionNANJING LUYE PHARMACEUTICALApr 17, 2020
EP2582697Nanostructured Aprepitant Compositions, Process For The Preparation Thereof And Pharmaceutical Compositions Containing ThemDRUGGABILITY HOLDCO JERSEYJun 27, 2018
EP3010962Preparation Of Polylactide-Polyglycolide Microparticles Having A Sigmoidal Release ProfilePHARMATHENApr 26, 2018

Explore Alkermes Pharma Ireland's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Patent NumberGrant DateTitleTotal Oppositions
EP2445502Sep 28, 2022Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders1
EP3182958May 18, 2022Aripiprazole Prodrug Compositions1
EP3253377May 12, 2021Monomethylfumarate Prodrug Compositions4
EP2970101Jun 6, 2018Prodrugs Of Fumarates And Their Use In Treating Various Deseases3